Brii Financial Statements From 2010 to 2025
| BRIBF Stock | USD 0.30 0.17 130.77% |
Check Brii Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brii Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Brii financial statements analysis is a perfect complement when working with Brii Biosciences Valuation or Volatility modules.
Brii |
Brii Biosciences Limited Company Current Valuation Analysis
Brii Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Brii Biosciences Current Valuation | 305.78 M |
Most of Brii Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brii Biosciences Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Brii Biosciences Limited has a Current Valuation of 305.78 M. This is 97.87% lower than that of the Healthcare sector and 93.42% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 98.16% higher than that of the company.
Brii Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Brii Biosciences's current stock value. Our valuation model uses many indicators to compare Brii Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Brii Biosciences competition to find correlations between indicators driving Brii Biosciences's intrinsic value. More Info.Brii Biosciences Limited is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Brii Biosciences' earnings, one of the primary drivers of an investment's value.About Brii Biosciences Financial Statements
Brii Biosciences stakeholders use historical fundamental indicators, such as Brii Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Brii Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Brii Biosciences' assets and liabilities are reflected in the revenues and expenses on Brii Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Brii Biosciences Limited. Please read more on our technical analysis and fundamental analysis pages.
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company was incorporated in 2017 and is based in Beijing, China. Brii Bioscience is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Brii Pink Sheet
Brii Biosciences financial ratios help investors to determine whether Brii Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Brii with respect to the benefits of owning Brii Biosciences security.